ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
ENDOLUNG试验。一项针对晚期/复发性子宫内膜癌患者的1/2期研究，旨在评估Akt/mTOR抑制剂和自噬诱导剂Ibrilatazar（ABTL0812）联合紫杉醇/卡铂的疗效。
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-024-12501-5
Leary, Alexandra; Estévez-García, Purificación; Sabatier, Renaud; Ray-Coquard, Isabelle; Romeo, Margarita; Barretina-Ginesta, Pilar; Gil-Martin, Marta; Garralda, Elena; Bosch-Barrera, Joaquim; Morán, Teresa; Martin-Martorell, Paloma; Nadal, Ernest; Gascón, Pere; Rodon, Jordi; Lizcano, Jose M; Muñoz-Guardiola, Pau; Fierro-Durán, Gemma; Pedrós-Gámez, Oriol; Pérez-Montoyo, Héctor; Yeste-Velasco, Marc; Cortal, Marc; Pérez-Campos, Antonio; Alfon, Jose; Domenech, Carles; Pérez-Fidalgo, Alejandro; Oaknin, Ana
